Preview

Архивъ внутренней медицины

Расширенный поиск

Место пациентов с промежуточной фракцией выброса левого желудочка в общей популяции больных хронической сердечной недостаточностью

https://doi.org/10.20514/2226-6704-2021-11-2-111-121

Полный текст:

Аннотация

В 2016г в рекомендациях Европейского общества кардиологов по диагностике и лечению острой и хронической сердечной недостаточности (ХСН) выделена новая группа пациентов с промежуточной фракцией выброса левого желудочка (пФВ ЛЖ), референтный интервал которой лежит в диапазоне 40-49 %. В представленном обзоре освещены вопросы эпидемиологии, этиологии и диагностики ХСНпФВ, профиль биомаркеров и динамические фенотипы пациентов, рассмотрены принципы лечения и факторы, определяющие прогноз заболевания. Особое внимание уделено особенностям формирования разнородной когорты пациентов и целесообразности расширения существующей на сегодняшний день классификации ХСНпФВ путем введения двух переходных фенотипов.

Об авторах

Н. Т. Ватутин
ГОО ВПО «Донецкий национальный медицинский университет им. М. Горького»; Институт неотложной и восстановительной хирургии им. В.К. Гусака
Украина

Донецк



А. Н. Шевелёк
ГОО ВПО «Донецкий национальный медицинский университет им. М. Горького»; Институт неотложной и восстановительной хирургии им. В.К. Гусака
Украина

Донецк



В. В. Венжега
ФГАОУ ВО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова» Министерства Здравоохранения Российской Федерации
Россия

Виктория Валериевна Венжега

Москва



Список литературы

1. Гарганеева А.А., Бауэр В.А., Борель К.Н. ПанедемияXXI века: хроническая сердечная недостаточность — бремя современного общества. Эпидемиологические аспекты (обзор литературы). Сибирский медицинский журнал. 2014; 29 (3):8-12. ISSN: 2073-8552.

2. Longjian L. Epidemiology of heart failure and scope of the problem. CardiologyClinics. 2014; 32:1–8. DOI: 10.1016/j.ccl.2013.09.009

3. Шляхто Е.В. Кардиология. Национальное руководство. Краткое издание / под ред. Е.В. Шляхто. — 2-е изд., перераб. и доп. — М.: ГЭОТАР-Медиа. 2018; 691-711. ISBN 978-5-9704-5397-1.

4. Ситникова М.Ю. Хроническая сердечная недостаточность: эпидемиология и перспективы планирования. Сердечная недостаточность. 2012; 6(74):372–376. ISSN: 1728-4651.

5. Lуpez_Sendуn J. The heart failure epidemic. Medicographia. 2011; 33:363–369. ISSN 0243-3397.

6. Ponikowski P, Voors A.A., Anker S.D.et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891–975. DOI: 10.1093/eurheartj/ehw128.

7. Bayés-Genís A., Núñez J., Lupón J. et al. Heart Failure with mid-range ejection fraction: a transition phenotype? European journal of Heart Failure. 2017:1-3. DOI: 10.1002/ejhf.977.

8. Lam C.S., Solomon S.D. The middle child in heart failure: heart failure with mid-rangeejection fraction (40–50 %). Eur J Heart Fail.2014;16:1049–1055. DOI: 10.1002/ejhf.159.

9. Dickstein K., Cohen-Solal A., Filippatos G. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2008; 29(19), 2388-2442. DOI: 10.1093/eurheartj/ehn309.

10. McMurray J.J., Adamopoulos S., Anker S.D. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787-847. DOI: 10.1093/eurheartj/ehs104. Epub 2012 May 19.

11. Lam C.S.P., Teng T..HK. Understanding Heart Failure With Mid-Range Ejection Fraction. JACC: Heart Failure 2016; 4(6):1-4. DOI: 10.1016/j.jchf.2016.03.025.

12. Andronic A.A., Mihaila S., Cinteza M. et al. Heart Failure with Mid- Range Ejection Fraction — a New Category of Heart Failure or Still a Gray Zone. MAEDICA — a Journal of Clinical Medicine. 2016; 11(4):320-324. PMID: 28828050.

13. Lauritsen J., Gustafsson F., Jawdat A. et al. Characteristics and longterm prognosis of patients with heart failure and mid-range ejection fraction compared with reduced and preserved ejection fraction: a systematic review and meta-analysis. ESC Heart Failure. 2018: 1-10. DOI: 10.1002/ehf2.12283.

14. Jeffrey J.H., Boback Z., Gregg C.F. et al. Heart Failure With Mid- Range (Borderline) Ejection Fraction Clinical Implications and Future Directions. JACC: Heart Failure. 2017; 5(11): 763-771. DOI: 10.1016/j.jchf.2017.06.013

15. Nauta J.F., Hummel Y.M., Melle J.P. et al. What have we learned about heart failure with mid-range ejection fraction one year after its introduction? European Journal of Heart Failure. 2017: 1-5. DOI:10.1002/ejhf.1058.

16. Yancy C.W., Januzzi J.L. Jr., Allen L.A., et al. 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2018;71:20-30. DOI: 10.1016/j.jacc.2017.11.025; PMID: 29277252.

17. Koh A.S., Tay W.T., Teng T.H.K. et al. A comprehensive populationbased characterization of heart failure with mid-range ejection fraction. European Journal of Heart Failure. 2017:1-11. DOI: 10.1002/ejhf.945.

18. Sartipy U., Dahlström U., Fu M. et al. Atrial Fibrillation in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction. JACC: Heart Failure. 2017:1-10. DOI: 10.1016/j.jchf.2017.05.001.

19. Farmakis D., Simitsis P., Vasiliki B. et al. Acute Heart Failure with midrange ejection fraction: clinical profile, in-hospital management and short term outcome. Clin Res Cardiol. 2016: 1-10.

20. Tsuji K., Sakata Y., Nochioka K. et al. Characterization of heart failure patients with mid-range left ventricular ejection fraction — a report from the CHART-2 Study. European journal of Heart Failure. 2017: 1-12. DOI: 10.1002/ejhf.807.

21. Chioncel O., Lainscak M., Seferovic P.M. et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. European Journal of Heart Failure. 2017; 12:1-12. DOI: 10.1002/ejhf.813.

22. Tromp J., Voors A.A., Lam C.S.P. Heart failure with mid-range ejection fraction: causes and consequences. European Journal of Heart Failure. 2018: 1-3. DOI: 10.1002/ejhf.1134.

23. Kapoor J.R., Kapoor R., Ju C. et al. Precipitating clinical factors, heart failure characterization, and outcomes in patients hospitalized with heart failure with reduced, borderline, and preserved ejection fraction. JACC Heart Fail. 2016;4:464–472. DOI: 10.1016/j.jchf.2016.02.017.

24. Koh A.S., Tay W.T., Teng T.H. et al. A comprehensive population-based characterization of heart failure with mid-range ejection fraction. Eur J Heart Fail. 2017;19:1624–1634. DOI: 10.1002/ejhf.945.

25. Vedin O., Lam C.S., Koh A.S. et al. Significance of ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: a nationwide cohort study. Circ Heart Fail.2017; 10(6):1-9 DOI: 10.1161/CIRCHEARTFAILURE.117.003875.

26. Chioncel O., Lainscak M., Seferovic P.M. et al. Epidemiology and oneyear outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail.2017; 19(12):1574-1585. DOI: 10.1002/ejhf.813.

27. Rickenbacher P., Kaufmann B.A., Maeder M.T. et al. Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Eur J Heart Fail 2017 12 15;19(12):1586-1596. DOI:10.1002/ejhf.798.

28. Yusuf S., Pfeffer M.A., Swedberg K. et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet Lond Engl. 2003;362:777–81. PMID: 13678871

29. Lufman I., Szummer K., Dahlstrцm U. et al. Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction. Eur J Heart Fail. 2017 Mar; 19(12):1606-1614. DOI: 10.1002/ejhf.821.

30. Sartipy U., Dahlström U., Fu M. et al. Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction. JACC Heart Fail.2017;5:565–574. DOI: 10.1016/j.jchf.2017.05.001.

31. He K.L., Burkhoff D., Leng W.X., et al.Comparison of ventricular structure andfunction in Chinese patients with heartfailure and ejection fractions >55 % versus40 % to 55 % versus <40 %. Am J Cardiol.2009;103:845–851. DOI: 10.1016/j.amjcard.2008.11.050.

32. Lang R.M., Badano L.P., Mor-Avi V. et al. Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging Guidelines and standards Journal of the American Society of Echocardiography Journal — Cardiovascular Imaging. 2015; 16, 233–271. DOI:10.1093/ehjci/jev014.

33. Moliner P., Lupón J., Barallat J. et al. A. Bio-profiling and bio-prognostication of chronic heart failure with mid-range ejection fraction. Int J Cardiol. 2017: 257:188-192. DOI:10.1016/j.ijcard.2018.01.119.

34. Tsuji K., Sakata Y., Nochioka K. et al. Characterization of heart failure patients with mid-range left ventricular ejection fraction—a report from the CHART-2 study. Eur. J. Heart Fail. 2017 Oct;19(10):1258-1269. DOI:10.1002/ejhf.807.

35. Bayes-Genis A., Nuñez-Villota J., Lupón J. Heart failure with midrange ejection fraction: a transition phenotype? Eur J Heart Fail. 2017 Dec;19(12):1635-1637. DOI:10.1002/ejhf.977.

36. Sanders-van Wijk S., Empel V., Davarzani N. et al. Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction. Eur J Heart Fail. 2015 Oct; 17(10):1006-14. DOI: 10.1002/ejhf.414.

37. Tromp J., Khan M.A.F., Mentz R.J. et al. Biomarker profiles of acute heart failure patientswith amid-range ejection fraction. JACC Heart Fail. 2017 Jul;5(7):507-517. DOI: 10.1016/j.jchf.2017.04.007.

38. Kociol R.D., Pang P.S., Gheorghiade M. et al. Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. J Am Coll Cardiol. 2010 Sep 28;56(14):1071-8. DOI: 10.1016/j.jacc.2010.06.016.

39. Bayés-Genís A., Barallat J., Galán A. et al. Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients. J Am Coll Cardiol. 2015 Feb 24;65(7):657-65. DOI: 10.1016/j.jacc.2014.11.048.

40. Bayes-Genis A., Barallat J., Lupón J. Soluble neprilysin does not correlate with outcome in heart failure with preserved ejection fraction? Eur J Heart Fail. 2016 Jan;18(1):89-93. DOI: 10.1002/ejhf.435.

41. Lupon J., Díez-Lуpez C., de Antonio M. et al. Recovered heart failure with reduced ejection fraction and outcomes: a prospective study. Eur J Heart Fail. 2017 Dec;19(12):1615-1623. DOI: 10.1002/ejhf.824.

42. Dunlay S.M., Roger V.L., Weston S.A. et al. Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ Heart Fail. 2012 Nov;5(6):720-6. DOI:10.1161/CIRCHEARTFAILURE.111.966366.

43. Rastogi A., Novak E., Platts A. et al. Epidemiology, pathophysiology and clinical outcomes for heart failure patients with a mid-range ejection fraction. Eur J Heart Fail. 2017 Dec;19(12):1597-1605. DOI: 10.1002/ejhf.879.

44. Unkovic P., Basuray A. Heart Failure with RecoveredEF and Heart Failurewith Mid-Range EF: CurrentRecommendationsand Controversies. Curr Treat Options Cardiovasc Med. 2018 Apr 3;20(4):35. DOI:10.1007/s11936-018-0628-9.

45. Clarke C.L., Grunwald G.K., Allen L.A. et al. Natural history of left ventricular ejection fraction in patients with heart failure. Circ Cardiovasc Qual Outcomes. 2013 Nov;6(6):680-6. DOI: 10.1161/CIRCOUTCOMES.111.000045.

46. Nadruz W.Jr., West E., Santos M. et al. Heart Failure and Midrange Ejection Fraction: Implications of Recovered Ejection Fraction for Exercise Tolerance and Outcomes. Circ Heart Fail. 2016 Apr;9(4):e002826. DOI: 10.1161/CIRCHEARTFAILURE.115.002826.

47. Basuray A., French B., Ky B. et al. Heart failure with recovered ejection fraction. Circulation. 2014 Jun 10;129(23):2380-7. DOI: 10.1161/CIRCULATIONAHA.113.006855.

48. Kalogeropoulos A.P., Fonarow G.C., Georgiopoulou V. et al. Characteristics and outcomes of adult outpatients with heart failure and improved or recovered ejection fraction. JAMA Cardiol. 2016 Aug 1;1(5):510-8. DOI: 10.1001/jamacardio.2016.1325.

49. Kelly J.P., Men R.J., Mebazaa A. et al. Patient selection in heart failure withpreserved ejection fraction clinical trials.J Am Coll Cardiol. 2015 Apr 28;65(16):1668-1682. DOI: 10.1016/j.jacc.2015.03.043.

50. Cheng R.K., Cox M., Neely M.L. et al. Outcomes in patients with heart failurewith preserved, borderline, and reducedejection fraction in the Medicarepopulation. Am Heart J. 2014 Nov;168(5):721-30. DOI: 10.1016/j.ahj.2014.07.008.

51. Pitt B., Pfeffer M.A., Assmann S.F.et al. TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014 Apr 10;370(15):1383-92. DOI: 10.1056/NEJMoa1313731.

52. Cleland J.G.F., Bunting K.V., Flather M.D.et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J. 2018 Jan 1;39(1):26-35. DOI: 10.1093/eurheartj/ehx564.

53. Lofman I., Szummer K., Dahlstrom U. et al. Associations withand prognostic impact of chronic kidney disease in heartfailure with preserved, mid-range, and reduced ejectionfraction. Eur J Heart Fail.2017;19:1606–14. DOI: 10.1002/ejhf.821;PMID: 28371075.

54. Nadar S.K., Tariq O. What is Heart Failure with Mid-range Ejection Fraction? A New Subgroup of Patients with Heart Failure. Cardiac Failure Review. 2018;4(1):6–8. DOI: https://doi.org/10.15420/cfr.2018:7:2.

55. Lund L.H., Claggett B., Liu J. et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. EurJHeart- Fail. 2018; DOI: 10.1002/ejhf.1149; PMID: 29431256.

56. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4083. doi:10.15829/1560-4071-2020-4083.

57. Chronic heart failure. Clinical recommendations 2020. Russian journal of cardiology. 2020; 25 (11): 4083. doi: 10.15829 / 1560-4071-2020-4083 [In Russian]

58. Леонова М.В. Европейский консенсус применения диуретиков при хронической сердечной недостаточности 2019 года. Медицинскийсовет. 2020;(4):12–21. doi: 10.21518/2079-701X-2020-4-12-21.

59. Seferovic P.M., Ponikowski P., Anker S.D.et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019 Oct;21(10):1169-1186. doi: 10.1002/ejhf.1531. Epub 2019 Aug 30. PMID: 31129923.

60. Pieske B., Tschöpe C., de Boer R.A. et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019 Oct 21;40(40):3297-3317. doi: 10.1093/eurheartj/ehz641. PMID: 31504452.

61. Nie D., Xiong B., Qian J.et al. The Effect of Sacubitril-Valsartan in Heart Failure Patients With Mid-Range and Preserved Ejection Fraction: A Meta-Analysis. Heart Lung Circ. 2020 Nov 13:S1443-9506(20)31475-X. doi: 10.1016/j.hlc.2020.10.012. Epub ahead of print. PMID: 33199181.

62. Lam C.S.P., Doehner W., Comin-Colet J.; IRON CORE Group. Iron deficiency in chronic heart failure: case-based practical guidance. ESC Heart Fail. 2018;5(5):764-771. doi: 10.1002/ehf2.12333.


Для цитирования:


Ватутин Н.Т., Шевелёк А.Н., Венжега В.В. Место пациентов с промежуточной фракцией выброса левого желудочка в общей популяции больных хронической сердечной недостаточностью. Архивъ внутренней медицины. 2021;11(2):111-121. https://doi.org/10.20514/2226-6704-2021-11-2-111-121

For citation:


Vatutin N.T., Shevelok A.N., Venzheha V.V. Position of Patients with Mid-Range Ejection Fraction in the General Chronic Heart Failure Population. The Russian Archives of Internal Medicine. 2021;11(2):111-121. https://doi.org/10.20514/2226-6704-2021-11-2-111-121

Просмотров: 262


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2226-6704 (Print)
ISSN 2411-6564 (Online)